Holen Sie sich die Stockscreener-App
102.55
6.50%
-7.13
Handel nachbörslich:
102.50
-0.05
-0.05%
Schlusskurs vom Vortag:
$109.68
Offen:
$110
24-Stunden-Volumen:
1.12M
Relative Volume:
1.77
Marktkapitalisierung:
$5.05B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-15.70
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
-6.87%
1M Leistung:
+1.85%
6M Leistung:
+0.27%
1J Leistung:
+19.17%
1-Tages-Spanne:
$102.54
$110.19
1-Wochen-Bereich:
$102.54
$113.98
52-Wochen-Spanne:
$72.21
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
102.55 | 5.42B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq
Is Axsome Therapeutics Inc. a good long term investmentFree Trend-Following Techniques - jammulinksnews.com
What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com
Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.'s 4th Largest Position - MarketBeat
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Mizuho reiterates Outperform rating on Axsome Therapeutics stock By Investing.com - Investing.com Canada
Axsome Therapeutics: Promising Growth Driven by Robust Pipeline and Strategic Fit - TipRanks
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by New York State Common Retirement Fund - MarketBeat
What analysts say about Axsome Therapeutics Inc. stockExtraordinary market timing - jammulinksnews.com
Axsome Therapeutics Rings the Opening Bell - Nasdaq
Axsome Therapeutics hosts frontiers in Brain Health R&D Day - TipRanks
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - Lelezard
Axsome Therapeutics: A CNS Pipeline with High-Impact Catalysts for Long-Term Growth - AInvest
Axsome Therapeutics Hosts R&D Day to Present Comprehensive Data on CNS Pipeline Targeting Alzheimer’s Disease, Depression, Narcolepsy, Fibromyalgia, ADHD, and Smoking Cessation - Nasdaq
Axsome Reveals New Phase 3 Data for 6 Major Brain Disorders: Expert Panel Discusses Breakthrough Treatments - Stock Titan
Axsome Celebrates New CNS Drug Launch with NASDAQ Bell Ringing, Unveils Brain Health Pipeline - Stock Titan
Axsome Therapeutics Inc. Stock Analysis and ForecastHigh-profit stock alerts - Autocar Professional
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Lindbrook Capital LLC - MarketBeat
Bank of New York Mellon Corp Has $15.28 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
William Blair Issues Negative Outlook for AXSM Earnings - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Mizuho reiterates Outperform rating on Axsome Therapeutics stock ahead of R&D Day - Investing.com Australia
Edgestream Partners L.P. Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 4.5% this past week - simplywall.st
Alps Advisors Inc. Has $3.78 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Long Term Investment Analysis - news.stocktradersdaily.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Iridian Asset Management LLC CT - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Penserra Capital Management LLC Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Stocks Showing Improving Market Leadership: Axsome Therapeutics Earns 85 RS Rating - MSN
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating - MSN
Axsome Therapeutics (AXSM) Soars 5.77% on Positive Analyst Ratings - AInvest
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 - 富途牛牛
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - The Manila Times
Axsome Therapeutics Scheduled to Report Q2 2025 Financial Results and Host Conference Call on August 4, 2025 - Nasdaq
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics shares rise 1.08% intraday as RBC Capital Markets maintains its stance on the biopharma company. - AInvest
Axsome Therapeutics (AXSM) Initiated with a Buy at Oppenheimer - The Globe and Mail
Axsome Therapeutics (AXSM) Gets a Buy from Wells Fargo - The Globe and Mail
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Cuts Target Price to $184 - 富途牛牛
Piper Sandler Reaffirms Price Target on Axsome (AXSM) Despite AXS-14 FDA Hurdle - MSN
Axsome Therapeutics to Host Frontiers in Brain Health R&D Day on July 21, 2025 - Nasdaq
Axsome Therapeutics to host brain health R&D day on July 21 - Investing.com
Axsome Therapeutics: A Bullish Play on Clinical Catalysts and Institutional Optimism - AInvest
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):